Galenica's 12.6% Underlying EBIT Growth Is Real-But 2.7x Leverage Caps the Upside

Galenica looks defensive, but leverage keeps the rerating conditional

The market is looking for a clean defensive winner, and Galenica has enough of the profile to attract attention. First-half sales grew 7.1% to CHF2.136 billion, reported EBIT reached CHF118 million, and underlying performance was stronger at 12.6% adjusted EBIT growth. In a nervous market, that combination can look reassuring.

Still, the story is not clean enough for a full valuation reset. Galenica's operating performance is credible, but the balance sheet still carries adjusted net debt of CHF837 million and 2.7x leverage. That does not signal distress. It does mean investors are likely to wait for evidence that operating gains can translate into financial flexibility.

Over the next few quarters, the key question is whether Galenica can turn good momentum into trust. If it does, the stock story can improve quickly. If not, the company may remain a solid operator with a restrained multiple.

The operating improvement came from the customer-facing network

Galenica delivered a solid first half, but the more important issue is what drove the result. The strength was concentrated in the parts of the network closest to patients and care users: local pharmacies grew 6.2%, while fee-paying consultations rose 27%. That suggests the business is moving deeper into care services, not simply relying on distribution volume.

Why the mix matters

A distribution business can look healthy for temporary reasons such as channel fills or a favorable product window. Galenica's quarter looks more durable because the better figures appeared alongside signs of a richer service mix. The company is expanding high-margin healthcare services, and the home care platform is being reinforced by the Bixel Home Care and Life Stage Solutions merger along with demand for services such as MediFill. LaborTeam also contributed 3.1% to sales growth. That mix points toward more repeat-driven activity and less dependence on simple product-cycle swings.

The weak spots actually support the durability argument

There were clear caveats. The Swiss OTC market was flat, and the products and brands segment saw an 8% sales decline. If the quarter had relied on OTC or brand sales, the result would be easier to dismiss as temporary. Instead, the healthier figures showed up in pharmacies and consultations at the same time the product mix softened. That is more consistent with genuine market-share gains and a changing customer proposition.

Management has also reaffirmed 2026 guidance and cited good momentum for the second half. That shifts the debate from whether the quarter was strong to whether the business-model shift is holding up.

Why leverage still limits the upside

The bull case still needs a financing test. Galenica looks more like a selective compounder than an automatic rerating story because the market still has to believe operating gains can be sustained with adjusted net debt of CHF837 million and 2.7x leverage. That is not a distress signal, but it is enough to make investors cautious.

Why the market may wait for stronger execution evidence

The next step is not more proof of demand. It is proof that debt pressure and working-capital demands are easing. If cash conversion improves, the leverage story becomes more credible. If those pressures persist, the stock may stay contained even if operations remain decent.

There is also a short-term management watchpoint. The LaborTeam CEO has left, which adds uncertainty during an active integration phase. That does not invalidate the strategy, but it does mean investors are still judging whether management can hold the pieces together while the balance sheet improves.

What to watch next

• 2.7x leverage moving lower
• No repeat of temporary inventory buildup tied to the ERP switch
• LaborTeam integration holding up after the CEO departure
• Second-half momentum remaining strong enough to support management's good momentum for the second half